May 17, 2016 – Vancouver, BC – Fundamental Research Corp., an independent research firm specializing in the small-cap and microcap sectors, has announced that it has initiated coverage of Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: BLVKF). The report includes a rating and a price target.
The 26-page report includes:
- Regenerative medicine and allograft market overviews
- Company background and legacy products
- Lead products
- Next generation ECM-based allograft technology
- Upcoming products
- High equity ownership
- Financials and operating performance.
Reports found above have been sent to Lattice Biologics Ltd., by courtesy of the banks and investment companies, for inclusion in the investor relations section of the website. Lattice Biologics Ltd. is not responsible for the content of these reports. These reports have not been prepared by Lattice Biologics Ltd., (“Lattice Biologics” or the “Company”) and Lattice Biologics does NOT adopt or endorse the contents hereof, which constitute the opinion solely of the report’s authors. Lattice Biologics disclaims any representation, either express or implied, that the information in these reports are accurate or that the statements in these reports reflects the Company’s views. Further, the Company disclaims any obligation to furnish any other published reports or updates, whether or not by the same authors and whether or not the contents thereof are consistent with the information and views expressed in these reports.